Archive

Arthritis pain rising: How state policies matter

Written by Charlie King | 19 Oct 2025

New research from The University of Texas at Arlington shows that differences in state welfare policies are linked to rising arthritis-related joint pain across much of the U.S…. read more.

Accurate and rapid arthritis diagnosis in just 10 minutes

Written by Charlie King | 11 May 2025

Dr. Ho Sang Jung and his research team from the Advanced Bio and Healthcare Materials Research Division at the Korea Institute of Materials Science (KIMS), in collaboration with Seoul… read more.

Protein blocking bone development could hold clues for future osteoporosis treatment

Written by Charlie King | 12 Oct 2024

Scientists have identified a protein that blocks the activity of bone-forming cells (osteoblasts) by stopping them from maturing during the journey to sites of bone formation, a new… read more.

New safety checklist aims to prevent side effects in patients with arthritis

Written by Charlie King | 8 Aug 2024

Inappropriate prescription of an antirheumatic drug for an unsuitable patient can lead to severe side effects such as intestinal perforations, blood clots, heart failure, or liver damage. To… read more.

New study shows perception of aging is linked to level of physical activity in arthritis patients

Written by Charlie King | 24 Nov 2023

People with arthritis who report more negative feelings about how they are aging tend to get less physical activity and perceive themselves as less healthy, according to a… read more.

FDA approves Cosentyx as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases – Novartis

Written by Charlie King | 22 Oct 2023

Novartis,, announced that the FDA has approved an intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic… read more.

New study reveals the most common form of arthritis, osteoarthritis, affects 15% of the global population over the age of 30

Written by Charlie King | 26 Aug 2023

A new study projects nearly 1 billion people will be living with osteoarthritis, the most common form of arthritis, by 2050. Currently, 15% of individuals aged 30 and… read more.

Study helps explain what drives psoriasis severity and offers clues as to how disease may spread to other body parts

Written by Charlie King | 7 Jun 2023

Beneath and beyond the reddish, flaky lesions that form in the skin of those with psoriasis, mild and severe forms of the disease can be told apart by… read more.

Managing anxiety and depression in arthritis

Written by Charlie King | 5 Jun 2023

Anxiety and depression are the mental health issues most commonly associated with inflammatory arthritis, and it is well-established that there is a link between mental health issues and… read more.

People with arthritis 20% less likely to be in work

Written by Charlie King | 31 Jan 2023

The typical person living with arthritis in the UK is 20% less likely to be in work than their equivalent without the condition, new research shows. And the… read more.

New study shows genes can predict response to arthritis treatment and paves the way for future drug development

Written by Charlie King | 31 May 2022

New research from Queen Mary University of London, published in Nature Medicine, has shown that molecular profiling of the diseased joint tissue can significantly impact whether specific drug treatments will… read more.

New comprehensive phase III data show first-in-class Tremfya provided durable improvements in measures of psoriatic arthritis through two years – Johnson & Johnson

Written by Charlie King | 24 Jan 2022

The Janssen Pharmaceutical Companies of Johnson & Johnson announced comprehensive efficacy and safety data from the DISCOVER–2 trial of Tremfya (guselkumab) were published in Arthritis & Rheumatology, representing… read more.

1 2 Next »

Archive

Subscribe for our mailing list

Follow Us